Literature DB >> 4943591

Chemotherapeutic evaluation of clotrimazole (Bay b 5097, 1 (o-chloro- - -diphenylbenzyl) imidazole).

J A Waitz, E L Moss, M J Weinstein.   

Abstract

Clotrimazole has a broad spectrum of activity against yeast and filamentous fungi in vitro and also in vivo when given orally or parenterally to experimentally infected mice and when administered orally or topically to infected guinea pigs. In vitro a distinct inoculum effect has been observed with a number of strains of Candida and Torulopsis; minimal inhibitory concentrations have tended to increase with increased incubation time. With prolonged incubation times, resistance can be developed to clotrimazole in vitro, but this resistance is readily reversible upon passage in drug-free broth. The degree of in vivo activity of clotrimazole against Candida depends on the severity of infection used. Orally it appears to be more effective when administered by gavage than when given mixed in the diet. Pretreatment with the agent may decrease its efficacy because of drug inactivation. Against dermatophytes, clotrimazole has a degree of activity similar to griseofulvin when given orally, but it is less active than tolnaftate topically in cutaneous infection of Trichophyton mentagrophytes in guinea pigs. In vitro, but not in vivo, some gram-positive and gram-negative bacteria are inhibited by low concentrations of clotrimazole.

Entities:  

Mesh:

Substances:

Year:  1971        PMID: 4943591      PMCID: PMC376440          DOI: 10.1128/am.22.5.891-898.1971

Source DB:  PubMed          Journal:  Appl Microbiol        ISSN: 0003-6919


  8 in total

1.  Biological activity of megalomicin, a new Micromonospora-produced macrolide antibiotic complex.

Authors:  J A Waitz; E L Moss; E M Oden; M J Weinstein
Journal:  J Antibiot (Tokyo)       Date:  1969-06       Impact factor: 2.649

2.  BAY b 5097, a new orally applicable antifungal substance with broad-spectrum activity.

Authors:  M Plempel; K Bartmann; K H Büchel; E Regel
Journal:  Antimicrob Agents Chemother (Bethesda)       Date:  1969

3.  In vivo studies with Bay b 5097.

Authors:  S Shadomy
Journal:  Antimicrob Agents Chemother (Bethesda)       Date:  1970

4.  [1st clinical experience with a new oral antimycotic in systemic mycoses].

Authors:  H Oberste-Lehn; I Baggesen; M Plempel
Journal:  Dtsch Med Wochenschr       Date:  1969-06-27       Impact factor: 0.628

5.  [Experimental findings on a new, orally active broad-spectrum antimycotic agent].

Authors:  M Plempel; K Bartmann; K H Büchel; E Regel
Journal:  Dtsch Med Wochenschr       Date:  1969-06-27       Impact factor: 0.628

6.  'Prophylactic' activity of tolnaftate in experimental Trichophyton mentagrophytes infections of guinea pigs.

Authors:  J A Waitz; E L Moss
Journal:  Chemotherapy       Date:  1969       Impact factor: 2.544

7.  [First experiences with the broad spectrum antimycotic BAY b 5097].

Authors:  W Marget; D Adam
Journal:  Med Klin       Date:  1969-07-04

8.  In vitro antifungal activity of clotrimazole (Bay b 5097).

Authors:  S Shadomy
Journal:  Infect Immun       Date:  1971-08       Impact factor: 3.441

  8 in total
  9 in total

Review 1.  New antifungal therapy in ophthalmology.

Authors:  T W Lieberman; I H Leopold
Journal:  Trans Am Ophthalmol Soc       Date:  1973

2.  In vitro activity of ME1401, a new antifungal agent.

Authors:  H Yamaguchi; K Uchida; T Hiratani; T Hara; H Fukuyasu; Y Kazuno; S Inouye
Journal:  Antimicrob Agents Chemother       Date:  1986-11       Impact factor: 5.191

3.  Sensitivity of strains of Candida albicans to jaritin, haloprogin, clotrimazole and miconazole.

Authors:  L Langsadl; Z Jedlickova
Journal:  Postgrad Med J       Date:  1979-09       Impact factor: 2.401

Review 4.  Clotrimazole: a review of its antifungal activity and therapeutic efficacy.

Authors:  P R Sawyer; R N Brogden; R M Pinder; T M Speight
Journal:  Drugs       Date:  1975       Impact factor: 9.546

5.  Inhibition of potentially pathogenic yeastlike fungi by clotrimazole in combination with 5-fluorocytosine or amphotericin B.

Authors:  W H Beggs; G A Sarosi; N M Steele
Journal:  Antimicrob Agents Chemother       Date:  1976-06       Impact factor: 5.191

6.  Clotrimazole (Bay b 5097): in vitro and clinical pharmacological studies.

Authors:  M A Burgess; G P Bodey
Journal:  Antimicrob Agents Chemother       Date:  1972-12       Impact factor: 5.191

7.  Anti-Candida activity of clotrimazole in combination with dioctyl sodium sulfosuccinate and other surfactants.

Authors:  K Iwata; H Yamaguchi
Journal:  Antimicrob Agents Chemother       Date:  1977-08       Impact factor: 5.191

Review 8.  Drug resistance in human pathogenic fungi.

Authors:  K Iwata
Journal:  Eur J Epidemiol       Date:  1992-05       Impact factor: 8.082

9.  Disk agar diffusion susceptibility testing of yeasts.

Authors:  M A Saubolle; P D Hoeprich
Journal:  Antimicrob Agents Chemother       Date:  1978-10       Impact factor: 5.191

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.